The global lung disease therapeutics market was valued at USD 76.5 billion in 2021 and is projected to surpass USD 109.4 billion by the end of 2031. The industry is expected to grow at a steady CAGR of 3.7% from 2022 to 2031, driven by the rising prevalence of respiratory disorders, increasing air pollution levels, and growing demand for advanced treatment options.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85362

Market Overview

Lung disease therapeutics include a range of drugs and treatments used to manage various lung conditions, including asthma, COPD, lung cancer, and idiopathic pulmonary fibrosis (IPF). The market is driven by factors such as a rise in the aging population, an increase in the rate of smoking, growth in air pollution, and a surge in awareness about lung diseases.

Some respiratory diseases are acute, such as an infection, and improve with treatment. Other diseases are chronic and must be managed. Chronic respiratory conditions can be caused by various lung diseases. Millions of people in the U.S. suffer from chronic respiratory diseases. Lung diseases are classified into specific conditions; hence, it is difficult to estimate how many people suffer from them.

Analysts’ Viewpoint

Lung disease therapeutics, such as drugs, are used to treat various lung diseases. High incidence and prevalence of Chronic Obstructive Pulmonary Disease (COPD) and rise in awareness programs are driving the global lung disease therapeutics market. Ongoing research & development activities and launch of products for the treatment of COPD are fueling market expansion. Advancements in technology, such as the development of biologic therapies, are expected to augment market progress in the near future.

Development of new approaches in therapeutic agent delivery, vaccine development, and nanotechnology-based medical detection is likely to present lucrative opportunities to market players. Companies are focusing on developing new drugs and treatments to improve treatment options for patients with lung disease.

Analysis of Key Players

The landscape is a high-stakes arena where traditional pharmaceutical giants are acquiring biotech startups to bolster their biologic pipelines.

Leading companies operating in the lung disease therapeutics market include:

• GSK
• AstraZeneca
• Boehringer Ingelheim
• Novartis
• Mylan
• Vertex Pharmaceuticals
• F. Hoffman La Roche
• Teva Pharmaceuticals
• Cipla
• Fibrogen
• Liminal Biosciences
• PharmAkea Therapeutics
• IQVIA

Strategic moves in 2026 show a focus on Triple-Combination Therapies, with AstraZeneca and GSK evaluating new formulations to reduce “exacerbation-related” hospitalizations, which remain a primary cost driver.

Recent Developments (2025–2026)

• In August 2022, AstraZeneca India announced a collaboration with Alveofit to provide IoT-enabled handheld spirometers in hospitals across the country. According to the vaccine manufacturer, this collaboration aims to incorporate the most recent technological advances in diagnosing and managing lung disorders and associated non-communicable diseases such as asthma, pulmonary fibrosis, and COPD.
• In July 2021, BREATHE and IQVIA announced a partnership to accelerate the early diagnosis and treatment of respiratory conditions. With clear strategic alignment, IQVIA joined BREATHE as a Supporting Partner to work together to improve health outcomes and quality of life for people living with respiratory conditions in the U.K.
• In November 2020, Bridge Biotherapeutics, Inc. and Boehringer Ingelheim International GmbH ended their collaboration on the experimental therapy BBT-877 for a type of lung disease. Bridge Biotherapeutics, Inc. will regain all rights to BBT-877, which is being developed to treat idiopathic pulmonary fibrosis and other fibrotic diseases.

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=85362

Key Developments & Trends

• Precision Biologics: Heavy investment in monoclonal antibodies targeting specific IL-4, IL-5, and IL-13 inflammatory pathways.
• Smart Drug Delivery: Widespread adoption of mesh nebulizers and digital “connected” inhalers for improved patient adherence.
• Triple-Therapy Expansion: Moving from dual to triple combinations (LAMA/LABA/ICS) as the first-line treatment for severe COPD.
• Stem Cell Feasibility: Successful Phase I/II trials confirming the safety of mesenchymal stromal cells for lung tissue regeneration.
• Home-Based Care: Rising demand for portable, tele-rehabilitation-compatible respiratory devices.

Challenges

• Underdiagnosis: Approximately 50% of COPD cases in developing nations remain undiagnosed due to limited access to spirometry.
• High Cost of Biologics: The price premium for targeted antibody therapies necessitates new pharmacoeconomic evaluations for reimbursement.
• Environmental Impact: Ongoing pressure to transition away from high-carbon-footprint propellant-based MDIs.
• Lack of Curative Options: Most current treatments focus on symptom suppression rather than reversing permanent lung damage.

Opportunities

• Asia-Pacific Expansion: Unmet demand in China and India due to aging populations and environmental irritants.
• Pediatric Asthma: Increasing prevalence in urban centers creates a massive market for child-friendly biologic delivery.
• Orphan Drugs: Incentives for developing therapeutics for rare diseases like Idiopathic Pulmonary Fibrosis (IPF) and Cystic Fibrosis.
• AI-Driven Diagnostics: Using machine learning to identify high-risk patients earlier through routine chest scans.

Market Segmentation

➤ By Disease Type

• Asthma (Largest Share in 2025/2026)
• Chronic Obstructive Pulmonary Disease (COPD)
• Lung Cancer (NSCLC & SCLC – Highest growth in value)
• Pulmonary Arterial Hypertension (PAH)
• Fibrosis and Infectious Diseases

➤ By Drug Class

• Corticosteroids (Traditional Market Leader)
• Bronchodilators (Beta-2 Agonists & Anticholinergics)
• Biologics (Monoclonal Antibodies – Fastest Growing)
• Phosphodiesterase Type 4 Inhibitors

➤ By Route of Administration

• Inhalation (Dominant ~53.9% share)
• Oral
• Injectable (Rising with Biologics)

➤ By Distribution Channel

• Hospital Pharmacies (Central role in acute care ~37.1%)
• Retail Pharmacies
• Online/E-Pharmacies (Rising for chronic maintenance)

Conclusion

The lung disease therapeutics market in 2026 is at the forefront of precision medicine. Through 2035, success will be defined by molecule specificity and delivery intelligence. As the industry pivots from “managing” symptoms to “modifying” the disease via biologics and regenerative tech, the companies that can bridge the gap between high-cost innovation and global accessibility will lead the respiratory landscape.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=85362&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trend analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany, NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com